Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
- 10 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 314-317
- https://doi.org/10.1016/j.clcc.2021.07.001
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsAnnals of Oncology, 2019
- Application of Cell-free DNA Analysis to Cancer TreatmentThe New England Journal of Medicine, 2018
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trialsAnnals of Oncology, 2017
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trialsEuropean Journal of Cancer, 2016
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsNature Medicine, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?Annals of Oncology, 2012